These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 27854216)

  • 21. Emerging Oligonucleotide Therapeutics for Rare Neuromuscular Diseases.
    Aoki Y; Wood MJA
    J Neuromuscul Dis; 2021; 8(6):869-884. PubMed ID: 34092651
    [TBL] [Abstract][Full Text] [Related]  

  • 22. RNA splicing manipulation: strategies to modify gene expression for a variety of therapeutic outcomes.
    Wilton SD; Fletcher S
    Curr Gene Ther; 2011 Aug; 11(4):259-75. PubMed ID: 21453280
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Exon skipping, a therapy for Duchenne muscular dystrophy. Interview by Guenter Scheuerbrandt.
    Platenburg G
    Acta Myol; 2008 Oct; 27():69-73. PubMed ID: 19364065
    [No Abstract]   [Full Text] [Related]  

  • 24. Exonic sequences provide better targets for antisense oligonucleotides than splice site sequences in the modulation of Duchenne muscular dystrophy splicing.
    Aartsma-Rus A; Houlleberghs H; van Deutekom JC; van Ommen GJ; 't Hoen PA
    Oligonucleotides; 2010 Apr; 20(2):69-77. PubMed ID: 20377429
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antisense oligonucleotides, exon skipping and the dystrophin gene transcript.
    Wilton SD; Fletcher S
    Acta Myol; 2005 Dec; 24(3):222-9. PubMed ID: 16629057
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Modulation of RNA Splicing by Oligonucleotides: Mechanisms of Action and Therapeutic Implications.
    Sergeeva OV; Shcherbinina EY; Shomron N; Zatsepin TS
    Nucleic Acid Ther; 2022 Jun; 32(3):123-138. PubMed ID: 35166605
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Splicing intervention for Duchenne muscular dystrophy.
    McClorey G; Fletcher S; Wilton S
    Curr Opin Pharmacol; 2005 Oct; 5(5):529-34. PubMed ID: 16085461
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Contributions of Japanese patients to development of antisense therapy for DMD.
    Matsuo M; Takeshima Y; Nishio H
    Brain Dev; 2016 Jan; 38(1):4-9. PubMed ID: 26094594
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Invention and Early History of Exon Skipping and Splice Modulation.
    Lim KRQ; Yokota T
    Methods Mol Biol; 2018; 1828():3-30. PubMed ID: 30171532
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ASO Therapy: Hope for Genetic Neurological Diseases.
    Muth CC
    JAMA; 2018 Feb; 319(7):644-646. PubMed ID: 29383373
    [No Abstract]   [Full Text] [Related]  

  • 31. Overview of gene therapy in spinal muscular atrophy and Duchenne muscular dystrophy.
    Abreu NJ; Waldrop MA
    Pediatr Pulmonol; 2021 Apr; 56(4):710-720. PubMed ID: 32886442
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Use of Tricyclo-DNA Oligomers for the Treatment of Genetic Disorders.
    Aupy P; Echevarría L; Relizani K; Goyenvalle A
    Biomedicines; 2017 Dec; 6(1):. PubMed ID: 29271929
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enhancing Antisense Oligonucleotide-Based Therapeutic Delivery with DG9, a Versatile Cell-Penetrating Peptide.
    Haque US; Yokota T
    Cells; 2023 Oct; 12(19):. PubMed ID: 37830609
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Advances in therapeutic RNA-targeting.
    van Ommen GJ; Aartsma-Rus A
    N Biotechnol; 2013 Mar; 30(3):299-301. PubMed ID: 23369867
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting RNA to treat neuromuscular disease.
    Muntoni F; Wood MJ
    Nat Rev Drug Discov; 2011 Aug; 10(8):621-37. PubMed ID: 21804598
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Innovative therapeutic approaches for hereditary neuromuscular diseases].
    Kirschner J; Schoser B
    Nervenarzt; 2018 Oct; 89(10):1115-1122. PubMed ID: 30171303
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Exon skipping in Duchenne's muscular dystrophy].
    Nau JY
    Rev Med Suisse; 2008 Jan; 4(140):176. PubMed ID: 18309885
    [No Abstract]   [Full Text] [Related]  

  • 38. Optimizing RNA/ENA chimeric antisense oligonucleotides using in vitro splicing.
    Takeshima Y; Yagi M; Matsuo M
    Methods Mol Biol; 2012; 867():131-41. PubMed ID: 22454059
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In silico screening based on predictive algorithms as a design tool for exon skipping oligonucleotides in Duchenne muscular dystrophy.
    Echigoya Y; Mouly V; Garcia L; Yokota T; Duddy W
    PLoS One; 2015; 10(3):e0120058. PubMed ID: 25816009
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vivo comparison of 2'-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping.
    Heemskerk HA; de Winter CL; de Kimpe SJ; van Kuik-Romeijn P; Heuvelmans N; Platenburg GJ; van Ommen GJ; van Deutekom JC; Aartsma-Rus A
    J Gene Med; 2009 Mar; 11(3):257-66. PubMed ID: 19140108
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.